EGFR and neoplasm: The distribution of age, sex, histological subtype, concurrent mutations, sites of metastasis, programmed death-ligand1 (PD-L1) expression status, and tumor-infiltrating lymphocyte (TIL) status across epidermal growth factor receptor (EGFR) mutation subtypes is summarized in Table 1.